Publications by Category - Cardiology
These publications were authored or co-authored by Quest Diagnostics staff.
Cost-effectiveness model of use of genetic testing as an aid in assessing the likely benefit of aspirin therapy for primary prevention of cardiovascular disease.Authors: Shiffman D, Slawsky K, Fusfeld L, Devlin JJ, Goss TF.
Clin Ther. 2012;34:1387-1394.
Novel lipoprotein subfraction and size measurements in prediction of mortality in maintenance hemodialysis patients.Authors: Noori N, Caulfield MP, Salameh WA, Reitz RE, Nicholas SB, Molnar MZ, Nissenson AR, Kovesdy CP, Kalantar-Zadeh K.
Clin J Am Soc Nephrol. 2011;6:2861-2870.
'Criteria' aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, Texas, April 2010.Authors: Pierangeli SS, de Groot PG, Dlott J, Favaloro E, Harris EN, Lakos G, Ortel T, Meroni PL, Otomo K, Pengo V, Tincani A, Wong R, Roubey R.
Testing for variants in CYP2C19: population frequencies and testing experience in a clinical laboratory.Quest Diagnostics Authors: Strom, C
Authors: Goos D, Crossley B, Zhang K, Buller-Burkle A, Jarvis M, Quan F, Peng M, Sun W.
Genet Med. 2012;14:95-100.
Genetic testing for early detection of individuals at risk of coronary heart disease and monitoring response to therapy: challenges and promises.Authors: Superko HR, Roberts R, Agatston A, Frohwein S, Reingold JS, White TJ, Sninsky JJ, Margolis B, Momary KM, Garrett BC, King SB, III.
Curr Atheroscler Rep. 2011;13:396-404.
Survival bias and drug interaction can attenuate cross-sectional case-control comparisons of genes with health outcomes. An example of the kinesin-like protein 6 (KIF6) Trp719Arg polymorphism and coronary heart disease.Authors: Williams P, Pendyala L, Superko R.
BMC Med Genet. 2011;12:42.